Shares of Sientra, Inc. (NASDAQ:SIEN) have earned a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $13.67.

Several research firms have weighed in on SIEN. Canaccord Genuity began coverage on shares of Sientra in a report on Monday, August 28th. They set a “buy” rating and a $14.00 price objective on the stock. Lake Street Capital restated a “buy” rating and set a $15.00 price objective (up previously from $11.00) on shares of Sientra in a report on Wednesday, August 2nd. William Blair upgraded shares of Sientra from a “market perform” rating to an “outperform” rating in a report on Wednesday. Stephens began coverage on shares of Sientra in a report on Tuesday, July 11th. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a report on Wednesday, May 17th.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SIEN. Gilder Gagnon Howe & Co. LLC raised its holdings in Sientra by 36.3% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,114,511 shares of the medical instruments supplier’s stock worth $10,833,000 after buying an additional 296,902 shares during the last quarter. Schroder Investment Management Group raised its holdings in Sientra by 146.1% during the first quarter. Schroder Investment Management Group now owns 417,733 shares of the medical instruments supplier’s stock worth $3,442,000 after buying an additional 247,992 shares during the last quarter. Bamco Inc. NY raised its holdings in Sientra by 109.3% during the second quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock worth $4,583,000 after buying an additional 246,183 shares during the last quarter. State Street Corp acquired a new position in Sientra during the second quarter worth $1,449,000. Finally, Northern Trust Corp raised its holdings in Sientra by 449.4% during the second quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock worth $1,451,000 after buying an additional 122,066 shares during the last quarter. Hedge funds and other institutional investors own 77.61% of the company’s stock.

Shares of Sientra (SIEN) opened at 12.58 on Wednesday. The firm has a 50-day moving average of $10.93 and a 200 day moving average of $9.29. Sientra has a 52 week low of $6.92 and a 52 week high of $13.09. The firm’s market capitalization is $242.87 million.

Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.04. Sientra had a negative net margin of 173.83% and a negative return on equity of 52.30%. The firm had revenue of $8.20 million for the quarter, compared to the consensus estimate of $6.97 million. The business’s revenue was up 32.3% on a year-over-year basis. On average, equities analysts predict that Sientra will post ($3.04) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sientra, Inc. (SIEN) Receives Average Rating of “Buy” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/09/13/sientra-inc-sien-receives-average-rating-of-buy-from-analysts.html.

Sientra Company Profile

Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.

Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.